Literature DB >> 20974566

SEOM clinical guidelines for the treatment of head and neck cancer.

Ricard Mesía Nin1, Miguel Pastor Borgoñón, Juan Jesús Cruz Hernández, Dolores Isla Casado.   

Abstract

Head and neck cancer constitutes the fifth highest cause of cancer in Spain. It is a neoplasm with a high possibility of cure if it is diagnosed in early stages, but unfortunately two thirds of the patients are diagnosed at an advanced loco-regional stage (stage III and IV, without metastasis). The multidisciplinary team, bringing together all professionals who specialize in the diagnosis and treatment of these tumors make the decision to establish the best sequence of individualized diagnosis, staging and treatment for each patient. This guide gives recommendations for diagnosis, staging and treatment for squamous cell carcinoma of the head and neck. In order to simplify the amount of information about any subsite of the head and neck area, the treatment recommendations are summarized as local disease, locally advance resectable and unresectable stages, function-preserving laryngeal treatment and recurrent and metastatic disease.

Entities:  

Mesh:

Year:  2010        PMID: 20974566     DOI: 10.1007/s12094-010-0589-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  14 in total

Review 1.  Head and neck cancer.

Authors:  A Forastiere; W Koch; A Trotti; D Sidransky
Journal:  N Engl J Med       Date:  2001-12-27       Impact factor: 91.245

2.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

3.  Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer.

Authors:  Gregory T Wolf; Susan Gross Fisher; Waun Ki Hong; Robert Hillman; Monica Spaulding; George E Laramore; James W Endicott; Kenneth McClatchey; William G Henderson
Journal:  N Engl J Med       Date:  1991-06-13       Impact factor: 91.245

Review 4.  Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis.

Authors:  Eric Winquist; Tom Oliver; Ralph Gilbert
Journal:  Head Neck       Date:  2007-01       Impact factor: 3.147

5.  Trends in smoking-related cancer incidence in Tarragona, Spain, 1980-96.

Authors:  J Borràs; J M Borràs; J Galceran; V Sánchez; V Moreno; J R González
Journal:  Cancer Causes Control       Date:  2001-12       Impact factor: 2.506

6.  Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors:  Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

7.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.

Authors:  Jan B Vermorken; Eva Remenar; Carla van Herpen; Thierry Gorlia; Ricard Mesia; Marian Degardin; John S Stewart; Svetislav Jelic; Jan Betka; Joachim H Preiss; Danielle van den Weyngaert; Ahmad Awada; Didier Cupissol; Heinz R Kienzer; Augustin Rey; Isabelle Desaunois; Jacques Bernier; Jean-Louis Lefebvre
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

8.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.

Authors:  Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad
Journal:  N Engl J Med       Date:  2007-10-25       Impact factor: 91.245

9.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival.

Authors:  James A Bonner; Paul M Harari; Jordi Giralt; Roger B Cohen; Christopher U Jones; Ranjan K Sur; David Raben; Jose Baselga; Sharon A Spencer; Junming Zhu; Hagop Youssoufian; Eric K Rowinsky; K Kian Ang
Journal:  Lancet Oncol       Date:  2009-11-10       Impact factor: 41.316

10.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.

Authors:  Yoann Pointreau; Pascal Garaud; Sophie Chapet; Christian Sire; Claude Tuchais; Jacques Tortochaux; Sandrine Faivre; Stephane Guerrif; Marc Alfonsi; Gilles Calais
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

View more
  4 in total

1.  The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.

Authors:  Dolores Isla Casado; Antonio González-Martín; Emilio Alba Conejo
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

2.  Multidisciplinary clinical approach to the management of head and neck cancer.

Authors:  Patrick J Bradley
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-10-16       Impact factor: 2.503

3.  Residual neck disease management in squamous-cell carcinoma of the head and neck treated with radiotherapy plus cetuximab.

Authors:  R Montal; M Oliva; M Taberna; L De Avila; A Rovira; M Cos; M Mañós; V Navarro; J Nogués; A Lozano; L Rodríguez; E Vilajosana; S Vázquez; R Mesia
Journal:  Clin Transl Oncol       Date:  2016-03-10       Impact factor: 3.405

4.  Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.

Authors:  I Pajares Bernad; J Martínez Trufero; L Calera Urquizu; R A Pazo Cid; A Cebollero de Miguel; M J Agustin; M Lanzuela; A Antón
Journal:  Clin Transl Oncol       Date:  2017-01-24       Impact factor: 3.340

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.